Evidence map›Paper›PMID 38716891›Full record

ReviewBiochemical Society transactions2024

Retrotransposons in embryogenesis and neurodevelopment.

Mary Jo Talley, Michelle S Longworth

Abstract readReview
In one paragraph

Review in Biochemical Society transactions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mary Jo TalleyDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, U.S.A.
Michelle S LongworthDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, U.S.A.ORCID 0000-0002-1313-1777

Funding

Interplay between LINE-1 retrotransposons, condensins, and IFNR01GM147138 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI Michelle S Longworth · 2023 to 2026
$1.6M
The role of retrotransposonable elements in neurodevelopment and diseaseF32HD114499 · NICHD · CLEVELAND CLINIC LERNER COM-CWRU · PI TALLEY, MARY · 2024 to 2025
$151k
NICHD NIH HHS F32 HD114499NIGMS NIH HHS R01 GM147138
6 · The paper itself

Abstract

Retrotransposable elements (RTEs) are genetic elements that can replicate and insert new copies into different genomic locations. RTEs have long been identified as 'parasitic genes', as their mobilization can cause mutations, DNA damage, and inflammation. Interestingly, high levels of retrotransposon activation are observed in early embryogenesis and neurodevelopment, suggesting that RTEs may possess functional roles during these stages of development. Recent studies demonstrate that RTEs can function as transcriptional regulatory elements through mechanisms such as chromatin organization and noncoding RNAs. It is clear, however, that RTE expression and activity must be restrained at some level during development, since overactivation of RTEs during neurodevelopment is associated with several developmental disorders. Further investigation is needed to understand the importance of RTE expression and activity during neurodevelopment and the balance between RTE-regulated development and RTE-mediated pathogenesis.

Indexed as

Embryonic DevelopmentRetroelementsAnimalsGene Expression Regulation, DevelopmentalHumansRetroelementsLINE-1neurodevelopmentneurodevelopmental disordersretrotransposon

Identifiers

PMID38716891
PMCPMC11346457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.